You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBisoprolol
Accession NumberDB00612  (APRD00257)
TypeSmall Molecule
GroupsApproved
DescriptionBisoprolol is a cardioselective β1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. Bisoprolol is structurally similar to metoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At lower doses (less than 20 mg daily), bisoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with daily doses of 20 mg or greater. Unlike propranolol and pindolol, bisoprolol does not exhibit membrane-stabilizing or sympathomimetic activity. Bisoprolol possesses a single chiral centre and is administered as a racemic mixture. Only l-bisoprolol exhibits significant β-blocking activity.
Structure
Thumb
Synonyms
(+-)-1-((alpha-(2-Isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol
(RS)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
Bisoprolol
Bisoprololum
External Identifiers
  • CL 297939
  • EMD 33512
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-bisoprololTablet5 mgOralAvanstra Inc2011-08-222014-08-21Canada
Ava-bisoprololTablet10 mgOralAvanstra Inc2011-08-222014-08-21Canada
BisoprololTablet10 mgOralSanis Health Inc2012-10-01Not applicableCanada
BisoprololTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
BisoprololTablet10 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
BisoprololTablet5 mgOralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
BisoprololTablet5 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
BisoprololTablet5 mgOralSanis Health Inc2012-10-01Not applicableCanada
Dom-bisoprololTablet5 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-bisoprololTablet10 mgOralDominion PharmacalNot applicableNot applicableCanada
Monocor -(10mg)Tablet10 mgOralBiovail Pharmaceuticals Canada Division Of Biovail Corporation2000-06-222005-03-10Canada
Monocor -(5mg)Tablet5 mgOralBiovail Pharmaceuticals Canada Division Of Biovail Corporation2000-06-222009-07-31Canada
Mylan-bisoprololTablet5 mgOralMylan Pharmaceuticals Ulc2012-05-02Not applicableCanada
Mylan-bisoprololTablet10 mgOralMylan Pharmaceuticals Ulc2012-05-02Not applicableCanada
Nu-bisoprololTablet5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-bisoprololTablet10 mgOralNu Pharm IncNot applicableNot applicableCanada
PHL-bisoprololTablet5 mgOralPharmel Inc2008-10-30Not applicableCanada
PHL-bisoprololTablet10 mgOralPharmel Inc2008-10-30Not applicableCanada
PMS-bisoprololTablet5 mgOralPharmascience Inc2007-12-18Not applicableCanada
PMS-bisoprololTablet10 mgOralPharmascience Inc2007-12-18Not applicableCanada
Pro-bisoprolol - 10Tablet10 mgOralPro Doc Limitee2008-07-04Not applicableCanada
Pro-bisoprolol - 5Tablet5 mgOralPro Doc Limitee2008-07-04Not applicableCanada
Sandoz BisoprololTablet5 mgOralSandoz Canada Incorporated2003-04-24Not applicableCanada
Sandoz BisoprololTablet10 mgOralSandoz Canada Incorporated2003-04-24Not applicableCanada
Teva-bisoprololTablet5 mgOralTeva Canada Limited2005-10-07Not applicableCanada
Teva-bisoprololTablet10 mgOralTeva Canada Limited2005-10-07Not applicableCanada
ZebetaTablet, film coated5 mg/1OralTeva Women's Health, Inc.1992-07-312016-10-31Us
ZebetaTablet, film coated10 mg/1OralTeva Women's Health, Inc.1992-07-312017-05-31Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bisoprololTablet5 mgOralApotex Inc2004-08-10Not applicableCanada
Apo-bisoprololTablet10 mgOralApotex Inc2004-08-10Not applicableCanada
Bisoprolol FumarateTablet10 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Bisoprolol FumarateTablet, film coated5 mg/1OralTeva Pharmaceuticals USA Inc2004-06-01Not applicableUs
Bisoprolol FumarateTablet, coated5 mg/1OralAmerican Health Packaging2011-08-01Not applicableUs
Bisoprolol FumarateTablet, film coated10 mg/1OralCitron Pharma LLC2006-12-27Not applicableUs
Bisoprolol FumarateTablet5 mg/1OralPreferred Pharmaceuticals, Inc.2016-10-24Not applicableUs
Bisoprolol FumarateTablet5 mg/1OralRebel Distributors Corp2009-09-21Not applicableUs
Bisoprolol FumarateTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2009-07-23Not applicableUs
Bisoprolol FumarateTablet, film coated10 mg/1OralTeva Pharmaceuticals USA Inc2004-06-01Not applicableUs
Bisoprolol FumarateTablet5 mg/1OralCarilion Materials Management2009-09-21Not applicableUs
Bisoprolol FumarateTablet5 mg/1Oralbryant ranch prepack2009-09-21Not applicableUs
Bisoprolol FumarateTablet, coated5 mg/1OralEon Labs, Inc.2000-11-16Not applicableUs
Bisoprolol FumarateTablet10 mg/1OralRebel Distributors Corp2009-09-21Not applicableUs
Bisoprolol FumarateTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2009-08-07Not applicableUs
Bisoprolol FumarateTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.2012-09-24Not applicableUs
Bisoprolol FumarateTablet, film coated5 mg/1OralAurobindo Pharma Limited2006-12-27Not applicableUs
Bisoprolol FumarateTablet, coated10 mg/1OralEon Labs, Inc.2000-11-16Not applicableUs
Bisoprolol FumarateTablet5 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Bisoprolol FumarateTablet, film coated5 mg/1OralCitron Pharma LLC2006-12-27Not applicableUs
Bisoprolol FumarateTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.2012-09-24Not applicableUs
Bisoprolol FumarateTablet, film coated10 mg/1OralAurobindo Pharma Limited2006-12-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CardicorBayer
ConcorMerck
ConcoreMerck
DetensielMerck Santé
EmconcorMerck
EmcorMerck
EuradalLacer
IsotenMeda
MonocorBiovail Pharmaceuticals
SoprolHelsinn
Brand mixtures
NameLabellerIngredients
Bisoprolol Fumarate and HydrochlorothiazideMylan Pharmaceuticals Inc.
ZiacTeva Women's Health, Inc.
Salts
Name/CASStructureProperties
Bisoprolol Fumarate
104344-23-2
Thumb
  • InChI Key: VMDFASMUILANOL-WXXKFALUSA-N
  • Monoisotopic Mass: 766.461575573
  • Average Mass: 766.97
DBSALT001015
Categories
UNIIY41JS2NL6U
CAS number66722-44-9
WeightAverage: 325.443
Monoisotopic: 325.225308485
Chemical FormulaC18H31NO4
InChI KeyVHYCDWMUTMEGQY-UHFFFAOYSA-N
InChI
InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
IUPAC Name
1-[(propan-2-yl)amino]-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
Pharmacology
IndicationFor management of heart failure, angina pectoris, and mild to moderate hypertension and for secondary prevention of myocardial infarction (MI).
Structured Indications
PharmacodynamicsBisoprolol is a competitive, cardioselective β1-adrenergic antagonist. Activation of β1-receptors (located mainly in the heart) by epinephrine increases heart rate and the blood pressure causing the heart to consume more oxygen. β1-adrenergic blocking agents such as bisopolol lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. They are routinely prescribed in patients with ischemic heart disease. In addition, β1-selective blockers prevent the release of renin, a hormone produced by the kidneys causes constriction of blood vessels. Bisoprolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane-stabilizing activity.
Mechanism of actionBisoprolol selectively blocks catecholamine stimulation of β1-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. At higher doses (e.g. 20 mg and greater) bisoprolol may competitively block β2-adrenergic receptors in bronchial and vascular smooth muscle causing bronchospasm and vasodilation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinno
antagonist
HumanP07550 details
Related Articles
AbsorptionWell absorbed. Bioavailability > 80%. Absorption is not affected by food. Peak plasma concentrations occur within 2-4 hours.
Volume of distributionNot Available
Protein bindingBinding to serum proteins is approximately 30%
Metabolism

Approximately 50% of the dose is metabolized primarily metabolized by CYP3A4 to inactive metabolites. In vitro studies have shown that bisoprolol is also metabolized by CYP2D6 though this does not appear to be clinically significant. Approximately half the administered dose is excreted in unchanged in urine.

Route of eliminationEliminated equally by renal and non-renal pathways. Approximately 50% of the total orally administered dose is excreted unchanged in urine with the remainder appearing as inactive metabolites. Less than 2% of the dose is excreted in the feces.
Half life9-12 hours; prolonged in the elderly and those with decreased renal function
ClearanceNot Available
ToxicityOral, mouse: LD50 = 100 mg/kg; Skin, rabbit: LD50 = 200 mg/kg; Skin, rat: LD50 = 500 mg/kg. Symptoms of overdose include congestive heart failure (marked by sudden weight gain, swelling of the legs, feet, and ankles, fatigue, and shortness of breath), difficult or labored breathing, low blood pressure, low blood sugar, and slow heartbeat.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bisoprolol Action PathwayDrug actionSMP00300
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bisoprolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bisoprolol.Experimental
AbirateroneThe serum concentration of Bisoprolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Bisoprolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bisoprolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideBisoprolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Bisoprolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Acetylcholine.Approved
AcetyldigitoxinBisoprolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bisoprolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Bisoprolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Bisoprolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Aliskiren.Approved, Investigational
AlprenololBisoprolol may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Bisoprolol.Approved
AmbrisentanBisoprolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateBisoprolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineBisoprolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bisoprolol.Approved
AminophyllineBisoprolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Bisoprolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Bisoprolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Bisoprolol.Approved, Illicit
AmodiaquineThe metabolism of Bisoprolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Bisoprolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bisoprolol.Approved
AnvirzelBisoprolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
AprepitantThe serum concentration of Bisoprolol can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineBisoprolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Arecoline.Experimental
ArformoterolBisoprolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bisoprolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Bisoprolol can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Bisoprolol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bisoprolol.Approved
AtomoxetineThe metabolism of Bisoprolol can be decreased when combined with Atomoxetine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bisoprolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bisoprolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
BambuterolBisoprolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Bisoprolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Bisoprolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Bisoprolol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Bisoprolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bisoprolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bisoprolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Illicit
BepridilBisoprolol may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantBisoprolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bisoprolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Bisoprolol.Investigational
BexaroteneThe serum concentration of Bisoprolol can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostBisoprolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Bisoprolol.Investigational
BoceprevirThe metabolism of Bisoprolol can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Bisoprolol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bisoprolol can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Bisoprolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bisoprolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Bisoprolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bisoprolol.Investigational
BucindololBisoprolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bisoprolol.Approved, Investigational
BupranololBisoprolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Bisoprolol can be decreased when combined with Bupropion.Approved
CabergolineBisoprolol may increase the vasoconstricting activities of Cabergoline.Approved
CalfactantBisoprolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Candesartan.Approved
CandoxatrilBisoprolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Bisoprolol can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Bisoprolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Bisoprolol.Approved
CarvedilolBisoprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bisoprolol.Experimental
CelecoxibThe metabolism of Bisoprolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololBisoprolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibBisoprolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bisoprolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe metabolism of Bisoprolol can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideBisoprolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bisoprolol.Approved
CholecalciferolThe metabolism of Bisoprolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Cilnidipine.Approved
CimetidineThe metabolism of Bisoprolol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Bisoprolol can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Bisoprolol can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Bisoprolol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bisoprolol can be decreased when combined with Clemastine.Approved
ClenbuterolBisoprolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Clevidipine.Approved
ClobazamThe metabolism of Bisoprolol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe metabolism of Bisoprolol can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bisoprolol.Approved
ClotrimazoleThe metabolism of Bisoprolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Bisoprolol can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Bisoprolol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Bisoprolol can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Bisoprolol can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Bisoprolol.Vet Approved
CrizotinibThe metabolism of Bisoprolol can be decreased when combined with Crizotinib.Approved
CryptenamineBisoprolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bisoprolol.Investigational
CyclosporineThe metabolism of Bisoprolol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Bisoprolol.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bisoprolol.Investigational
DabrafenibThe serum concentration of Bisoprolol can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Bisoprolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Bisoprolol can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Bisoprolol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Bisoprolol can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinBisoprolol may increase the hypotensive activities of Debrisoquin.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Bisoprolol.Approved
DeferasiroxThe serum concentration of Bisoprolol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Bisoprolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Bisoprolol.Approved
DeserpidineBisoprolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Desflurane.Approved
DesipramineThe metabolism of Bisoprolol can be decreased when combined with Desipramine.Approved
DeslanosideBisoprolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bisoprolol can be increased when it is combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Bisoprolol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bisoprolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bisoprolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Diclofenamide.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Bisoprolol.Approved
DigitoxinBisoprolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinDigoxin may increase the bradycardic activities of Bisoprolol.Approved
DihydralazineBisoprolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Bisoprolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Bisoprolol can be decreased when combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bisoprolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bisoprolol.Approved
DobutamineBisoprolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Bisoprolol.Approved
DorzolamideBisoprolol may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinBisoprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxycyclineThe metabolism of Bisoprolol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneDronedarone may increase the bradycardic activities of Bisoprolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bisoprolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
DuloxetineBisoprolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bisoprolol.Investigational
DyphyllineBisoprolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Bisoprolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Bisoprolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bisoprolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bisoprolol.Approved
EfavirenzThe serum concentration of Bisoprolol can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineBisoprolol may increase the hypotensive activities of Efonidipine.Approved
EliglustatThe metabolism of Bisoprolol can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Bisoprolol.Approved, Vet Approved
EnalaprilatBisoprolol may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Bisoprolol can be decreased when it is combined with Enzalutamide.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Bisoprolol is combined with EPIBATIDINE.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bisoprolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Eplerenone.Approved
EpoprostenolBisoprolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Eprosartan.Approved
Ergoloid mesylateBisoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBisoprolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
ErythromycinThe metabolism of Bisoprolol can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Bisoprolol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bisoprolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bisoprolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
EtoperidoneThe serum concentration of Bisoprolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
EtravirineThe serum concentration of Bisoprolol can be decreased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bisoprolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Bisoprolol.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Bisoprolol.Approved
FenoldopamBisoprolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
FenoterolBisoprolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Bisoprolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bisoprolol.Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Fimasartan.Approved
FingolimodBisoprolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bisoprolol.Approved, Withdrawn
FluconazoleThe metabolism of Bisoprolol can be decreased when combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Bisoprolol.Vet Approved
FluoxetineThe metabolism of Bisoprolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bisoprolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
FluvoxamineThe metabolism of Bisoprolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolBisoprolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Bisoprolol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bisoprolol can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bisoprolol.Approved
FosphenytoinThe metabolism of Bisoprolol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bisoprolol can be increased when it is combined with Fusidic Acid.Approved
GalantamineGalantamine may increase the bradycardic activities of Bisoprolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bisoprolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bisoprolol.Approved, Nutraceutical
GlibornurideBisoprolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideBisoprolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBisoprolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBisoprolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBisoprolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideBisoprolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideBisoprolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bisoprolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Bisoprolol.Approved
GuanethidineBisoprolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
HaloperidolThe metabolism of Bisoprolol can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Halothane.Approved, Vet Approved
HexamethoniumBisoprolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Bisoprolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Bisoprolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Bisoprolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bisoprolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Bisoprolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBisoprolol may increase the hypotensive activities of Hydroflumethiazide.Approved
HydroxychloroquineThe metabolism of Bisoprolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bisoprolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bisoprolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bisoprolol.Approved
IdelalisibThe serum concentration of Bisoprolol can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Bisoprolol.Approved, Investigational
ImatinibThe metabolism of Bisoprolol can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Imidapril.Investigational
ImipramineThe metabolism of Bisoprolol can be decreased when combined with Imipramine.Approved
IndacaterolBisoprolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Bisoprolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Indapamide.Approved
IndenololBisoprolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Bisoprolol can be decreased when combined with Indinavir.Approved
IndomethacinIndomethacin may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bisoprolol.Withdrawn
IndoraminBisoprolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBisoprolol may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypotensive activities of Bisoprolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bisoprolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Bisoprolol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bisoprolol.Approved
IsoetarineBisoprolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Bisoprolol.Approved, Withdrawn
IsoniazidThe metabolism of Bisoprolol can be decreased when combined with Isoniazid.Approved
IsoprenalineBisoprolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Bisoprolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Bisoprolol.Approved
ItraconazoleThe metabolism of Bisoprolol can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineBisoprolol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Bisoprolol can be increased when it is combined with Ivacaftor.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Bisoprolol.Experimental
KetanserinBisoprolol may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Bisoprolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bisoprolol.Approved
LabetalolBisoprolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineBisoprolol may increase the hypotensive activities of Lacidipine.Approved
LacosamideBisoprolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideBisoprolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostBisoprolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Bisoprolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Levobupivacaine.Approved
LevodopaBisoprolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Bisoprolol can be increased when it is combined with Levomilnacipran.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Levosimendan.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bisoprolol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Bisoprolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
LopinavirThe metabolism of Bisoprolol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Bisoprolol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Bisoprolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Losartan.Approved
LovastatinThe metabolism of Bisoprolol can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
LucinactantBisoprolol may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Bisoprolol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Bisoprolol can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Bisoprolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
MacitentanBisoprolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bisoprolol.Approved
MalathionMalathion may increase the bradycardic activities of Bisoprolol.Approved, Investigational
ManidipineBisoprolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bisoprolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Bisoprolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bisoprolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bisoprolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bisoprolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bisoprolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bisoprolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bisoprolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Bisoprolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methacholine.Approved
MethadoneThe metabolism of Bisoprolol can be decreased when combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bisoprolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Bisoprolol.Approved
MethotrimeprazineThe metabolism of Bisoprolol can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisoprolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bisoprolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bisoprolol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Bisoprolol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bisoprolol.Approved, Investigational
MetyrosineBisoprolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilBisoprolol may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineBisoprolol may increase the bradycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Bisoprolol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Bisoprolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Bisoprolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Bisoprolol.Approved
MirabegronThe metabolism of Bisoprolol can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Bisoprolol can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Bisoprolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Bisoprolol.Approved
ModafinilThe serum concentration of Bisoprolol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Bisoprolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Bisoprolol.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Morphine.Approved, Investigational
MoxonidineBisoprolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bisoprolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Bisoprolol.Approved
NadololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bisoprolol.Investigational
NafcillinThe serum concentration of Bisoprolol can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the antihypertensive activities of Bisoprolol.Approved
NaftopidilBisoprolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
NCX 4016NCX 4016 may decrease the antihypertensive activities of Bisoprolol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Bisoprolol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Bisoprolol can be decreased when combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Bisoprolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bisoprolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Bisoprolol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bisoprolol can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Bisoprolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Bisoprolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Bisoprolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
NiguldipineBisoprolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Bisoprolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineBisoprolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Bisoprolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bisoprolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bisoprolol.Approved
NitrendipineBisoprolol may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bisoprolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Bisoprolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
ObinutuzumabBisoprolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bisoprolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Bisoprolol.Approved, Investigational
OlaparibThe metabolism of Bisoprolol can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bisoprolol.Approved, Investigational
OlodaterolBisoprolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Bisoprolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bisoprolol.Approved
OmapatrilatBisoprolol may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineBisoprolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bisoprolol.Vet Approved
OsimertinibThe serum concentration of Bisoprolol can be increased when it is combined with Osimertinib.Approved
OuabainBisoprolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bisoprolol.Approved
OxprenololBisoprolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bisoprolol.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Bisoprolol can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
PanobinostatThe serum concentration of Bisoprolol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Papaverine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Bisoprolol.Approved
PargylinePargyline may increase the hypotensive activities of Bisoprolol.Approved
ParoxetineThe metabolism of Bisoprolol can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideBisoprolol may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Bisoprolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Bisoprolol can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumBisoprolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bisoprolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Bisoprolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Bisoprolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Bisoprolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bisoprolol.Withdrawn
PhenobarbitalThe metabolism of Bisoprolol can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineBisoprolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bisoprolol.Withdrawn
PhentolamineBisoprolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Bisoprolol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Bisoprolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
PinacidilBisoprolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Pipamperone.Approved
PirbuterolBisoprolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Bisoprolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Bisoprolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Bisoprolol.Withdrawn
PolythiazideBisoprolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaBisoprolol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Bisoprolol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Pramipexole.Approved, Investigational
PrazosinBisoprolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bisoprolol can be decreased when combined with Primaquine.Approved
PrimidoneThe metabolism of Bisoprolol can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolBisoprolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
PromazineThe metabolism of Bisoprolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bisoprolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Bisoprolol.Approved
PropafenoneThe serum concentration of Bisoprolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bisoprolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Bisoprolol.Approved, Investigational
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bisoprolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bisoprolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Bisoprolol can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Bisoprolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Bisoprolol.Approved
RanolazineThe metabolism of Bisoprolol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Bisoprolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bisoprolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Bisoprolol.Approved
RescinnamineBisoprolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Bisoprolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Bisoprolol.Experimental, Investigational
RifabutinThe metabolism of Bisoprolol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bisoprolol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bisoprolol can be increased when combined with Rifapentine.Approved
RilmenidineBisoprolol may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Riociguat.Approved
RisperidoneBisoprolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineBisoprolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe metabolism of Bisoprolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabBisoprolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Bisoprolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bisoprolol.Investigational, Withdrawn
RolapitantThe metabolism of Bisoprolol can be decreased when combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Bisoprolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Bisoprolol.Withdrawn
SalbutamolBisoprolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Bisoprolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
SalmeterolBisoprolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bisoprolol.Approved
SaprisartanBisoprolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Bisoprolol can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bisoprolol.Approved, Investigational, Vet Approved
SelexipagBisoprolol may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
SertralineThe metabolism of Bisoprolol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Bisoprolol.Approved, Investigational
SilodosinBisoprolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SiltuximabThe serum concentration of Bisoprolol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bisoprolol can be increased when it is combined with Simeprevir.Approved
SitaxentanBisoprolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Bisoprolol.Approved
SpiraprilBisoprolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bisoprolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bisoprolol.Investigational
St. John's WortThe serum concentration of Bisoprolol can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Bisoprolol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Streptokinase.Approved
SufentanilBisoprolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bisoprolol.Approved
SulfisoxazoleThe metabolism of Bisoprolol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the antihypertensive activities of Bisoprolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Bisoprolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Bisoprolol.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Bisoprolol.Approved, Investigational
TamsulosinBisoprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TelaprevirThe metabolism of Bisoprolol can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Bisoprolol can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Telmisartan.Approved, Investigational
TemocaprilBisoprolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Bisoprolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bisoprolol.Vet Approved
TerazosinBisoprolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Bisoprolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineBisoprolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bisoprolol.Approved
TerlipressinBisoprolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineBisoprolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bisoprolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
ThioridazineThe metabolism of Bisoprolol can be decreased when combined with Thioridazine.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bisoprolol.Approved
TiboloneBisoprolol may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Bisoprolol can be decreased when combined with Ticlopidine.Approved
TicrynafenBisoprolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Bisoprolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bisoprolol.Investigational
TipranavirThe metabolism of Bisoprolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
TocilizumabThe serum concentration of Bisoprolol can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Bisoprolol.Approved, Investigational
TolazamideBisoprolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineBisoprolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideBisoprolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bisoprolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Bisoprolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Bisoprolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Bisoprolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bisoprolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bisoprolol.Experimental
TranylcypromineThe metabolism of Bisoprolol can be decreased when combined with Tranylcypromine.Approved
TravoprostTravoprost may increase the hypotensive activities of Bisoprolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Bisoprolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bisoprolol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Bisoprolol.Vet Approved
TrichlormethiazideBisoprolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bisoprolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bisoprolol.Approved, Vet Approved
TrimazosinBisoprolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanBisoprolol may increase the hypotensive activities of Trimethaphan.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Bisoprolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Bisoprolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Bisoprolol.Approved, Investigational
UnoprostoneBisoprolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bisoprolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bisoprolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bisoprolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe metabolism of Bisoprolol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Verapamil.Approved
VilanterolBisoprolol may decrease the bronchodilatory activities of Vilanterol.Approved
VinpocetineBisoprolol may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Bisoprolol can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Bisoprolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Bisoprolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bisoprolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Bisoprolol can be decreased when combined with Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Bisoprolol.Withdrawn
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Yoshihiro Iwao, Katsuyuki Ookubo, Katsuhiro Okada, Kunihiro Minami, Shuichiro Yuasa, “Adhesive Pharmaceutical Preparation Containing Bisoprolol.” U.S. Patent US20090169604, issued July 02, 2009.

US20090169604
General ReferencesNot Available
External Links
ATC CodesC07BB07C09BX02C07FB07C07AB57C07AB07
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9445
Blood Brain Barrier-0.9077
Caco-2 permeable+0.6149
P-glycoprotein substrateSubstrate0.7785
P-glycoprotein inhibitor INon-inhibitor0.807
P-glycoprotein inhibitor IINon-inhibitor0.7821
Renal organic cation transporterNon-inhibitor0.8568
CYP450 2C9 substrateNon-substrate0.8134
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6113
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9485
CYP450 3A4 inhibitorNon-inhibitor0.8373
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9766
Ames testNon AMES toxic0.9064
CarcinogenicityNon-carcinogens0.9267
BiodegradationNot ready biodegradable0.8962
Rat acute toxicity2.0089 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7877
hERG inhibition (predictor II)Non-inhibitor0.6611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Aurobindo pharma ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Unichem pharmaceuticals (usa) inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
TabletOral
Tablet, coatedOral
Tablet, film coatedOral
TabletOral10 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Condylox 0.5% Gel 3.5 gm Tube304.93USD tube
Condylox 0.5% Solution 3.5ml Bottle143.4USD bottle
Condylox 0.5% gel97.73USD g
Zebeta 10 mg tablet3.6USD tablet
Zebeta 5 mg tablet3.6USD tablet
Bisoprolol fumarate 5 mg tablet1.78USD tablet
Bisoprolol fumarate 10 mg tablet1.24USD tablet
Bisoprolol-Hydrochlorothiazide 10-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 2.5-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 5-6.25 mg tablet1.19USD tablet
Apo-Bisoprolol 10 mg Tablet0.38USD tablet
Novo-Bisoprolol 10 mg Tablet0.38USD tablet
Pms-Bisoprolol 10 mg Tablet0.38USD tablet
Sandoz Bisoprolol 10 mg Tablet0.38USD tablet
Apo-Bisoprolol 5 mg Tablet0.23USD tablet
Novo-Bisoprolol 5 mg Tablet0.23USD tablet
Pms-Bisoprolol 5 mg Tablet0.23USD tablet
Sandoz Bisoprolol 5 mg Tablet0.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point100 °CPhysProp
water solubility2240 mg/LNot Available
logP1.87RECANATINI,M (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.0707 mg/mLALOGPS
logP2.3ALOGPS
logP2.2ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area59.95 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity92.15 m3·mol-1ChemAxon
Polarizability38.5 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzylethers
Direct ParentBenzylethers
Alternative Parents
Substituents
  • Benzylether
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Breed JG, Ciampricotti R, Tromp GP, Valster FA, Lageweg E, Van Bortel LM: Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol. 1992;20(5):750-5. [PubMed:1280737 ]
  2. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145 ]
  3. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE: The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4. [PubMed:16325050 ]
  4. Lipworth BJ, Irvine NA, McDevitt DG: A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol. 1991;40(2):135-9. [PubMed:1676675 ]
  5. Mauz AB, Pelzer H: Beta-adrenoceptor-binding studies of the cardioselective beta blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two beta 1-binding sites for bisoprolol. J Cardiovasc Pharmacol. 1990 Mar;15(3):421-7. [PubMed:1691366 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145 ]
  2. Bruck H, Poller U, Lussenhop H, Ponicke K, Temme T, Heusch G, Philipp T, Brodde OE: Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):361-8. Epub 2004 Oct 23. [PubMed:15526107 ]
  3. Motomura S, Reinhard-Zerkowski H, Daul A, Brodde OE: On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am Heart J. 1990 Mar;119(3 Pt 1):608-19. [PubMed:1968697 ]
  4. Brodde OE: Bisoprolol (EMD 33512), a highly selective beta 1-adrenoceptor antagonist: in vitro and in vivo studies. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S29-35. [PubMed:2439795 ]
  5. Daul A, Johnston T, Reher M, Kruger M, Brodde OE: Differential haemodynamic effects induced by beta 1-(bisoprolol) or beta 2-(ICI 118,551) adrenoceptor blockade in man. J Hypertens Suppl. 1986 Dec;4(6):S99-102. [PubMed:2886573 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998 Mar;87(3):289-94. [PubMed:9523980 ]
  2. Horikiri Y, Suzuki T, Mizobe M: Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108. [PubMed:9763205 ]
  3. Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, Kato B, Igawa A, Inoue H: Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol. 2005 Nov;46(5):713-20. [PubMed:16220080 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998 Mar;87(3):289-94. [PubMed:9523980 ]
  2. Horikiri Y, Suzuki T, Mizobe M: Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108. [PubMed:9763205 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46